Vaccination against COVID-19, Influenza, and Pneumococcal Disease in the Elderly

Vaccination against COVID-19, Influenza, and Pneumococcal Disease in the Elderly - CIP-Vac

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00037801

Enrollment

7200

Registered

2025-09-08

Start date

2025-10-08

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

J00-J06 J09-J18 J20-J22 B97.2 B97.4 U07.1

Interventions

Group 1: Patients aged 60 years and older who are hospitalized due to a respiratory tract infection and have a positive test for Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2), infl

Eligibility

Sex/Gender

All

Age

60 Years to No maximum

Inclusion criteria

Inclusion criteria: Hospitalization, sufficient knowledge of German, informed consent, positive test for exactly one (case) or none (control) of the pathogens under investigation (SARS-CoV-2, influenza virus, pneumococci), negative RSV test

Exclusion criteria

Exclusion criteria: Lack of ability to provide informed consent, palliative treatment, prior enrollment in the present study, transfer from another hospital facility (except in the case of pneumococcal infection)

Design outcomes

Primary

Measure	Time frame
Vaccine effectiveness (VE) of COVID-19 and influenza vaccination for the endpoint of hospitalization due to SARS-CoV-2– or influenza virus–associated respiratory tract infection in the first year after booster vaccination. VE will be determined by assessing vaccination status within five months after study enrollment.	—

Secondary

Measure	Time frame
Vaccine effectiveness (VE) of pneumococcal vaccination for the endpoint of hospitalization with invasive pneumococcal disease and VE comparisons in subgroups of the study cohort. For VE comparisons, the study population will be stratified by time since last vaccination, type of vaccine received, age, presence of highly prevalent comorbidities/risk factors for severe disease, respiratory symptoms, and requirement for intensive care and mechanical ventilation. Variables will be collected for up to two months after hospital admission using study-specific questionnaires and review of medical records.	—

Measure

Time frame

Vaccine effectiveness (VE) of pneumococcal vaccination for the endpoint of hospitalization with invasive pneumococcal disease and VE comparisons in subgroups of the study cohort. For VE comparisons, the study population will be stratified by time since last vaccination, type of vaccine received, age, presence of highly prevalent comorbidities/risk factors for severe disease, respiratory symptoms, and requirement for intensive care and mechanical ventilation. Variables will be collected for up to two months after hospital admission using study-specific questionnaires and review of medical records.

—

Countries

Germany

Contacts

Public ContactKlaus Überla

Virologisches Institut - Universitätsklinikum Erlangen

klaus.ueberla@uk-erlangen.de+49 9131 85-32035

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: May 1, 2026